The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: An Open-Label, Dose-Escalation Study of AZD2461
Official Title: An Open-Label, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics fo the PARP Inhibitor AZD2461 in Patients With Refractory Solid Tumors
Study ID: NCT01247168
Brief Summary: This study is being conducted to test study drug AZD2461 to see how it may work to treat solid tumors. The main purpose of this study is to determine the safety and tolerability of AZD2461. This is the first time the drug has been given to humans and is classed as a first time in man study. Its main purpose is to establish a safe dosage of the drug and provide additional information on any potential side effects this drug may cause. The study will also assess the blood levels and action of AZD2461 in the body over a period of time and will indicate whether the drug has a therapeutic effect on solid tumors.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Research Site, Nashville, Tennessee, United States
Name: Andrew Hughes, MA, MB, ChB, PhD, P
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Name: Dr. Jeffrey Infante, MD
Affiliation: Sarah Cannon Research Institute (SCRI)
Role: PRINCIPAL_INVESTIGATOR